Intellia Therapeutics short interest was 44.41% of the float on June 30th, according to new data we received from Benzinga. Short interest totaled 49,218,272 shares, which was a decrease of -2.19% from June 15th.
It is estimated that it would take 7.54 days for short sellers to buy back their shares, with current trading volumes.
Intellia Therapeutics Hedge Fund Activity
We have seen 158 institutional investors add shares of Intellia Therapeutics stock to their portfolio, and 104 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TWO SIGMA INVESTMENTS, LP added 2,007,163 shares (+74.4%) to their portfolio in Q1 2026, for an estimated $25,731,829
- BLACKROCK, INC. added 1,878,957 shares (+18.3%) to their portfolio in Q1 2026, for an estimated $24,088,228
- UBS GROUP AG added 1,829,934 shares (+212.9%) to their portfolio in Q1 2026, for an estimated $23,459,753
- RENAISSANCE TECHNOLOGIES LLC removed 1,672,700 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $21,444,014
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP added 1,397,243 shares (+inf%) to their portfolio in Q1 2026, for an estimated $17,912,655
- CONTRARIUS GROUP HOLDINGS LTD added 1,197,359 shares (+167.6%) to their portfolio in Q1 2026, for an estimated $15,350,142
- ARMISTICE CAPITAL, LLC removed 820,000 shares (-70.9%) from their portfolio in Q1 2026, for an estimated $10,512,400
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Intellia Therapeutics Insider Trading Activity
Intellia Therapeutics insiders have traded $NTLA stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $NTLA stock by insiders over the last 6 months:
- EDWARD J III DULAC (EVP, Chief Financial Officer) sold 4,677 shares for an estimated $84,186
- MICHAEL P DUBE (VP, Chief Accounting Officer) sold 2,641 shares for an estimated $44,315
- JAMES BASTA (EVP, General Counsel) sold 1,211 shares for an estimated $16,687
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Intellia Therapeutics Price Targets
Multiple analysts have issued price targets for $NTLA recently. We have seen 13 analysts offer price targets for $NTLA in the last 6 months, with a median target of $17.0.
Here are some recent targets:
- Whitney Ijem from Canaccord Genuity set a target price of $49.0 on 06/16/2026
- Silvan Turkcan from Citizens set a target price of $30.0 on 06/15/2026
- David Nierengarten from Wedbush set a target price of $12.0 on 06/15/2026
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $25.0 on 06/15/2026
- William Pickering from Bernstein set a target price of $17.0 on 05/13/2026
- Terence Flynn from Morgan Stanley set a target price of $15.0 on 04/28/2026
- Salveen Richter from Goldman Sachs set a target price of $9.0 on 04/28/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
